GlassScriptPhysician profile
Nidal Alkafarna
NPI 1053796136
$6,209.42
in general payments reported to CMS, 2019-2025
12 companies · $999 in 2025
The $999 reported for 2025 was more than what 90% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $973 · 2023: $341 · 2024: $3,294 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923 · Travel and Lodging: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.92 |
| Travel and Lodging | $1,711.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,983.09 | 2024-2025 | Synergy Ablation System |
| Getinge USA Sales, LLC | $1,053.33 | 2021-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Abbott Laboratories | $802.10 | 2021-2024 | Epic |
| Medical Device Business Services, INC. | $510.46 | 2024 | Evarrest |
| Stryker Corporation | $427.03 | 2021-2025 | 1788, Na, Spy-Phi System |
| Ethicon US, LLC | $392.02 | 2024 | Surgiflo Hemostatic Matrix, Stratafix |
| Baxter Healthcare | $306.21 | 2021-2024 | Floseal, Preveleak, Coseal |
| Medtronic, INC. | $291.44 | 2021-2022 | |
| Edwards Lifesciences Corporation | $175.00 | 2025 | Sapien 3 Ultra Resilia |
| Davol INC. | $146.46 | 2021 | |
| Abiomed | $90.12 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.16 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Alkafarna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.